Tocilizumab, Remdesivir and Favipiravir repurposed for COVID-19: The Good, The Bad and The Ugly.
Mina T. Kelleni, MD, PhD
Assistant Professor of Pharmacology, College of Medicine, Minia University, Egypt
Mobile: +201200382422,
email: mina.kelleni@mu.edu.eg, drthabetpharm@yahoo.com
https://orcid.org/0000-0001-6290-6025
Key summary points:
Tocilizumab might have a potential to treat some critical cases of COVID-19 though the results of phase III clinical trials have been less than expected
Remdesivir, though its FDA approval, is very unlikely to benefit COVID-19 patients
Favipiravir is least likely to safely manage COVID-19 patients and it’s potentially teratogenic if given to pregnant patients